Back to Search
Start Over
Cyclophosphamide, vincristine, adriamycin, and dimethyl-triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital tract
- Source :
- Gynecologic Oncology. 14:319-323
- Publication Year :
- 1982
- Publisher :
- Elsevier BV, 1982.
-
Abstract
- From 1976 to 1981, 26 patients with sarcomas of the female genital tract were treated with combination chemotherapy consisting of cyclophosphamide, vincristine, adriamycin, and dimethyl-triazeno imidazole carboxamide (CYVADIC). Twenty-three percent achieved an objective response including complete response in 11.5%. The 23% response rate was achieved in patients who had extensive prior treatment with other chemotherapeutic regimens and/or radiation therapy. Therefore, the use of CYVADIC as first-line chemotherapy for sarcomas of the female genital tract not amenable to surgery or radiation therapy may result in significantly higher response rates than the 23% in the present series.
- Subjects :
- Female circumcision
Vincristine
medicine.medical_specialty
Cyclophosphamide
Genital Neoplasms, Female
medicine.medical_treatment
Urology
Antineoplastic Agents
Pharmacology
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Prospective Studies
Imidazole carboxamide
Ovarian Neoplasms
Chemotherapy
business.industry
Obstetrics and Gynecology
Sarcoma
Combination chemotherapy
Dacarbazine
Radiation therapy
Oncology
Doxorubicin
Cyclophosphamide/vincristine
Uterine Neoplasms
Drug Therapy, Combination
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 00908258
- Volume :
- 14
- Database :
- OpenAIRE
- Journal :
- Gynecologic Oncology
- Accession number :
- edsair.doi.dedup.....c2b2fbbac11b1fd1d2bf9856a4976a34